Analysts Set Immunic, Inc. (NASDAQ:IMUX) PT at $9.50

Shares of Immunic, Inc. (NASDAQ:IMUX) have been assigned a consensus rating of “Moderate Buy” from the seven ratings firms that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, five have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $9.50.

A number of research analysts have weighed in on IMUX shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immunic in a research report on Wednesday, October 8th. Chardan Capital started coverage on shares of Immunic in a research report on Monday, September 29th. They issued a “buy” rating and a $13.00 price objective for the company. HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Immunic in a research report on Friday, September 26th. LADENBURG THALM/SH SH raised shares of Immunic to a “strong-buy” rating in a research note on Thursday, October 16th. Finally, D. Boral Capital reissued a “buy” rating and set a $10.00 target price on shares of Immunic in a research note on Thursday, September 25th.

Institutional Trading of Immunic

A number of institutional investors and hedge funds have recently modified their holdings of IMUX. HB Wealth Management LLC purchased a new stake in Immunic during the 3rd quarter valued at about $81,000. Jane Street Group LLC grew its stake in Immunic by 279.3% during the 1st quarter. Jane Street Group LLC now owns 207,401 shares of the company’s stock valued at $226,000 after acquiring an additional 152,726 shares in the last quarter. 683 Capital Management LLC grew its stake in Immunic by 28.6% during the 1st quarter. 683 Capital Management LLC now owns 900,000 shares of the company’s stock valued at $981,000 after acquiring an additional 200,000 shares in the last quarter. Aberdeen Group plc purchased a new stake in Immunic during the 1st quarter valued at about $1,155,000. Finally, Focus Partners Wealth grew its stake in Immunic by 19.1% during the 1st quarter. Focus Partners Wealth now owns 2,583,457 shares of the company’s stock valued at $2,816,000 after acquiring an additional 415,104 shares in the last quarter. Hedge funds and other institutional investors own 51.82% of the company’s stock.

Immunic Stock Performance

Shares of Immunic stock opened at $0.84 on Friday. The firm has a 50-day simple moving average of $0.86 and a two-hundred day simple moving average of $0.89. The company has a market cap of $82.86 million, a P/E ratio of -0.89 and a beta of 1.56. Immunic has a fifty-two week low of $0.56 and a fifty-two week high of $1.42.

Immunic (NASDAQ:IMUX) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.02). Equities research analysts forecast that Immunic will post -0.94 EPS for the current year.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.